LLY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	3.49M
Average Volume	3.06M
Market Cap	690.55B
EPS	$0 ( 2024-02-06 )
Next earnings date	( $2.61 ) 2024-04-25
Last Dividend	$1.130 ( 2023-11-14 )
Next Dividend	$0 ( N/A )
P/E	124.80
ATR14	$0.895 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Sulzberger Gabrielle	Buy	13	Common Stock
2024-04-15	Luciano Juan R	Buy	20	Common Stock
2024-04-15	Johnson Kimberly H	Buy	13	Common Stock
2024-04-15	Hedley Mary Lynne	Buy	13	Common Stock
2024-04-15	Alvarez Ralph	Buy	16	Common Stock

INSIDER POWER
-42.38
Last 100 transactions
Buy: 207 692 \| Sell: 512 083

Volume Correlation

Long: -0.01 (neutral)

Short: 0.74 (moderate)

Signal:(50.485) Neutral

Eli Lilly and Co Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eli Lilly and Co Correlation - Currency/Commodity

-0.40
( neutral )

-0.37
( neutral )

-0.30
( neutral )

-0.70
( moderate negative )

0.18
( neutral )

Eli Lilly and Co Financials

Annual	2023
Revenue:	$34.12B
Gross Profit:	$27.55B (80.73 %)
EPS:	$5.82

Q4	2023
Revenue:	$9.35B
Gross Profit:	$7.69B (82.26 %)
EPS:	$2.31

Q3	2023
Revenue:	$9.50B
Gross Profit:	$7.64B (80.42 %)
EPS:	$-0.0638

Q2	2023
Revenue:	$8.31B
Gross Profit:	$6.50B (78.26 %)
EPS:	$1.960

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.980 (N/A)	$0.980 (N/A)	$1.130 (N/A)	$1.130 (N/A)	$2.26 (N/A)	$1.130 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Eli Lilly and Co Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.68 - average (56.44%) | Divividend Growth Potential Score: 6.05 - Stable (21.06%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0114	1972-08-07
Last Dividend	$1.130	2023-11-14
Next Dividend	$0	N/A
Payout Date	2023-12-08
Next Payout Date	N/A
# dividends	207	--
Total Paid Out	$60.68	--
Avg. Dividend % Per Year	1.12%	--
Score	4.71	--
Div. Sustainability Score	5.68
Div.Growth Potential Score	6.05
Div. Directional Score	5.87	--

Next Divdend (Est)
(2024-07-01)

$1.141 Estimate 39.90 %

Dividend Stability

0.80 Good

Dividend Score

4.71

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.0228	0.56%
1973	$0.0494	1.00%
1974	$0.0606	1.32%
1975	$0.0688	1.64%
1976	$0.0782	2.44%
1977	$0.0888	3.01%
1978	$0.103	4.37%
1979	$0.122	4.06%
1980	$0.137	3.79%
1981	$0.144	3.64%
1982	$0.162	4.67%
1983	$0.172	4.79%
1984	$0.186	5.00%
1985	$0.200	4.94%
1986	$0.225	3.28%
1987	$0.250	2.69%
1988	$0.288	2.88%
1989	$0.337	3.15%
1990	$0.412	2.40%
1991	$0.500	2.75%
1992	$0.552	2.60%
1993	$0.604	3.94%
1994	$0.624	4.20%
1995	$0.654	4.01%
1996	$0.684	2.47%
1997	$0.740	2.04%
1998	$0.800	1.16%
1999	$0.920	1.07%
2000	$1.040	1.59%
2001	$1.120	1.22%
2002	$1.240	1.58%
2003	$1.340	2.05%
2004	$1.420	1.99%
2005	$1.520	2.70%
2006	$1.600	2.79%
2007	$1.700	3.25%
2008	$1.880	3.58%
2009	$1.960	4.83%
2010	$1.960	5.47%
2011	$1.960	5.60%
2012	$1.960	4.69%
2013	$1.960	3.96%
2014	$1.960	3.86%
2015	$2.00	2.85%
2016	$2.04	2.46%
2017	$2.08	2.79%
2018	$2.25	2.66%
2019	$2.58	2.25%
2020	$2.96	2.24%
2021	$3.40	2.05%
2022	$3.92	1.44%
2023	$5.65	1.55%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.154	1.500	6.93	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0819	1.200	7.27	8.73	[0 - 0.3]
returnOnEquityTTM	0.474	1.500	5.85	8.77	[0.1 - 1]
payoutRatioTTM	0.777	-1.000	2.23	-2.23	[0 - 1]
currentRatioTTM	0.943	0.800	-0.287	-0.230	[1 - 3]
quickRatioTTM	0.523	0.800	-1.632	-1.305	[0.8 - 2.5]
cashRatioTTM	0.103	1.500	-0.537	-0.806	[0.2 - 2]
debtRatioTTM	0.394	-1.500	3.43	-5.15	[0 - 0.6]
interestCoverageTTM	16.19	1.000	5.11	5.11	[3 - 30]
operatingCashFlowPerShareTTM	4.47	2.00	8.51	10.00	[0 - 30]
freeCashFlowPerShareTTM	-3.32	2.00	-1.660	-3.32	[0 - 20]
debtEquityRatioTTM	2.34	-1.500	0.633	-0.949	[0 - 2.5]
grossProfitMarginTTM	0.796	1.000	0.0627	0.0627	[0.2 - 0.8]
operatingProfitMarginTTM	0.209	1.000	7.81	7.81	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.168	1.000	-0.177	-0.177	[0.2 - 2]
assetTurnoverTTM	0.533	0.800	9.78	7.82	[0.5 - 2]
Total Score				5.68

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	138.04	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.474	2.50	7.33	8.77	[0.1 - 1.5]
freeCashFlowPerShareTTM	-3.32	2.00	-1.107	-3.32	[0 - 30]
dividendYielPercentageTTM	0.616	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.47	2.00	8.51	10.00	[0 - 30]
payoutRatioTTM	0.777	1.500	2.23	-2.23	[0 - 1]
pegRatioTTM	76.96	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.124	1.000	9.39	0	[0.1 - 0.5]
Total Score				6.05

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Realtime updates for Eli Lilly and Co [LLY]

Upcoming Earnings Alert

Eli Lilly and Co Dividend Information - Dividend Knight

Dividend Commentary

Top 10 dividend Companies for NYSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)